Carisoprodol NDC 52536-688

NDC codes

FDA NDC Directory

Product NDC (as listed)52536-688Labeler and product segments. Claims need a package NDC.

Product NDC at billing width52536-0688Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
52536-688-10	52536068810	100 TABLET in 1 BOTTLE (52536-688-10)Marketed from Feb 15, 2017

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Carisoprodol
Generic name (nonproprietary): carisoprodol
Active ingredients: Carisoprodol — 350 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Wilshire Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 205126
Marketing start: Feb 15, 2017
Marketing end: Mar 31, 2027
DEA schedule: CIV
Other FDA classes: Centrally-mediated Muscle Relaxation (Physiologic effect)
Identifiers: Product ID 52536-688_292b367f-9427-b730-e063-6394a90ad340SPL ID 292b367f-9427-b730-e063-6394a90ad340SPL set ID f03a1ea6-20c1-406a-a5b6-00f1a056d9ffRxCUI 197446, 730794UNII 21925K482H
Pharmacologic class: Muscle Relaxant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N452536068810 followed by a unit qualifier and the quantity

Package 52536-0688-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 13, 2024.

Indications (excerpt from the label)

Carisoprodol Tablets, USP are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Carisoprodol Tablets, USP are a muscle relaxant indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults ( 1 ) Limitation of Use Should only be used for acute treatment periods up to two or three weeks ( 1 ) Limitation of Use Carisoprodol tablets should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [see Dosage and Adminis…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 205126

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 205126
Product	Strength	Form · route	Labeler	Product NDC
Carisoprodol	Carisoprodol 250 mg/1	TabletOral	Wilshire Pharmaceuticals, Inc.	52536-682